The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | M | Musculo-skeletal system | |
| 2 | M05 | Drugs for treatment of bone diseases | |
| 3 | M05B | Drugs affecting bone structure and mineralization | |
| 4 | M05BX | Other drugs affecting bone structure and mineralization | |
| 5 | M05BX03 | Strontium ranelate |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 2 g |
| Active Ingredient | Description | |
|---|---|---|
| Strontium ranelate |
In vitro, strontium ranelate increases bone formation in bone tissue culture as well as osteoblast precursor replication and collagen synthesis in bone cell culture and reduces bone resorption by decreasing osteoclast differentiation and resorbing activity. This results in a rebalance of bone turnover in favour of bone formation. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
